Keep up with the mass amount of information about COVID-19 being rolled out online. In this perspective we present three of this week’s COVID-19 headlines from Reuters, Medscape & The Lancet.

More perspectives on their way

For more than two weeks we have been sharing a daily COVID-19 Perspective with you, and we are overwhelmed by the interest and positive feedback. The average opening rate of over 50% tells us that this initiative is well received. We will keep following the news about COVID-19 and pick the most perspectives to share with you, but from Easter onwards we will decrease the cadence to twice a week. Every Thursday you will receive our most popular theme: COVID-19 in the big journals, and every Tuesday we will send you another COVID-19 ‘must-read’ perspective. If you have feedback or ideas for the next COVID-19 Perspective, please do not hesitate to let us know on a direct line to Editor-in-Chief Jan Andreasen: jan@bpno.dk

Inflammatory bowel disease is not normally associated with an increased risk of infections. However, immune modulating therapy entails a general higher risk for both bacterial and viral infections. This interrelation could be relevant in the current outbreak of COVID-19 where infected patients undergoing immune modulating therapy are thought to have increased risk for severe and complicated disease course. “Danish Society of Gastroenterology and Hepatology” has recommended to maintain the immune modulating therapy during the epidemy but endorse extra caution and awareness of preventing transmission.   By Johan Burisch, MD, PhD, Gastrounit, Medical division, Copenhagen University Hospital Hvidovre  Klaus Theede, chief physician, MD, PhD, Gastrounit, Medical division, Copenhagen University Hospital Hvidovre  Inflammatory bowel disease (IBD) is, despite the underlying dysregulation of the innate immune system, not necessarily associated with a higher risk of infection. However, the patients become immunosuppressed and thus have an increased risk of getting serious opportunistic infections by the therapy they receive, first and foremost the use of prednisolone, thiopurines, methotrexate and biological medicines, including antibodies against tumor necrosis factor alpha (anti-TNF-alpha).1  Every group of medicines entails a higher risk of infections. It is difficult to quantify the exact risks, that is known to variate from the different medicine groups. But it must be assumed that the immunosuppression increases when combining more than one drug. For instance, one international study found that the relative risk for opportunistic infections increased from an odds ratio on 2,9 (95% Cl: 1,5-5,3) when using one immune modulating drug to 14,5% (95% Cl: 4,9-43) when using two or more immune modulating drugs.2   In…

Inter-Agency Standing Committee has launched a $2 billion response plan in order to assist these countries. Read about the plan in this perspective.

SARS-CoV-2 – Man-made or natural?

Rumors about the origin of the virus SARS-CoV-2 causing COVID-19 are continuously circulating the globe, conspiring about if the virus is a man-made product of genetic manipulation or a lab-escape.

Covid-19 – The Search for Effective Therapy

Covid-19 is spreading rapidly in the whole world, but we only have few tools to control the epidemic and treat those who are sick.

Tweets by WHO

Tweets by THL